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Introduction 
    Diabetes has been one of the crucial non-
communicable diseases (NCDs) across the world [1]. 
Its prevalence has been increasing in developed and 
developing countries [2]. It may bring a variety of 
influences in the light of medical and economic aspects 
[3]. Regarding diabetic treatments, several options 
have been introduced, including oral hypoglycemic 
agents (OHAs) and injectable agents [4].  
 
    For the development of various treatment agents for 
diabetes, a recent important topic includes glucagon-
like peptide 1 (GLP-1) receptor agonist (GLP-1RA) [5]. 
After GLP-1RA showed clinical efficacy for diabetes, the 
combination of basal insulin and GLP-1RA was 
proposed for more beneficial efficacy [6]. There have 
been fixed-ratio combined agents with basal degludec 
and liraglutide and are known as Xultophy (IDegLira) 
[7]. 
 
    Its beneficial effects of these combined agents are 
observed [6]. In other words, they show 
complementary efficacy on glucose variability from 
degludec  and  liraglutide.   The  former   degludec  can   
Abstract 
The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include 
persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy 
on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative 
for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has 
been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of 
degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was 
improved satisfactory, suggesting the dual synergistic effects. 
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lower fasting plasma glucose (FPG), and the latter can 
lower FPG and decrease postprandial glucose response 
[8]. Moreover, the latter can improve beta-cell 
function and restore prandial insulin 
response/cardioprotective properties [9]. 
 
    As to the fixed-ratio combination of IDegLira, there 
was a study of the DUAL (Dual Action of Liraglutide 
and Insulin Degludec) clinical trial program [10,11]. 
The safety and effect were investigated in a series of 
DUAL programs. They showed that the superior or 
noninferior glycemic control was found with several 
comparators, associated with the benefit for lower risk 
of hypoglycemia and weight gain in comparison with 
other insulin agents [12,13].  
 
    Regarding diabetic practice, authors and 
collaborators have continued a variety of research. 
They include low carbohydrate diet (LCD), calorie 
restriction (CR), meal tolerance test (MTT), continuous 
glucose monitoring (CGM), treatment of insulin, GLP-
1RA and Xultophy, and so on [14,15]. Especially, we 
have applied Xultophy to patients with multiple 
problems and dialysis [16,17]. Xultophy has been 
known to be clinically effective for patients with 
various diseased states such as renal insufficiency or 
chronic renal failure, or limited treatment options [18]. 
This would be due to the beneficial efficacy of 
combined pharmacological agents. Authors have 
experienced an impressive diabetic case who has 
changed the treatment of multiple daily injection 
(MDI) insulin therapy to dulaglutide and also to 
Xultophy. In this article, general clinical progress 
associated with some discussion will be presented. 
 
Case Presentation 
Present History:  
    The patient is a 56-year old female. As a medical 
history, diabetes was detected at 35 years old (yo), 
urinary tract stones at 43 yo, hypertension from 45 yo, 
photocoagulation for diabetic retinopathy from 54 yo, 
and surgery for cataract at 55 yo. A space-occupying 
lesion (SOL) 2 cm in size was found in her left adrenal 
gland at a medical examination in June 2020. An 
endocrinological examination for adrenal tumors was 
performed at another hospital in July. As a result, the 
excessive  concentration of  cortisol  and catecholamine  
 
 
was denied. The value of HbA1c has been elevated at a 
high value of 8-9%. 
 
Physical Examination:  
    Her consciousness was alert, and her vitals are 
stable, such as body temperature 36.8, pulse 87/min, 
BP 112/67 mmHg. Her physique showed stature 151.2 
cm, weight 58.6 kg, standard weight 50.2 kg, BMI 25.6 
kg/m2, abdominal circumference 87cm. Skin showed 
normal turgor, no thyromegaly, no swollen lymph 
nodes. Conjunctiva was not anemic or icteric. Her 
chest showed regular rate rhythm in the heart and no 
rale in the lung. The abdomen was slightly distended, 
and extremities showed no pretibial edema. There 
were no clear signs of the moon face, buffalo hump, or 
central obesity. Neurologically, there were no sensory 
abnormalities such as peripheral neuropathy. 
 
Examination Data: 
    The results of laboratory exams were shown in the 
following. The standard biochemical data were GOT 23 
U/mL, GPT 27 U/mL, r-GTP 24 U/mL, Cre 0.7 mg/dL, 
BUN 19 mg/dL, Uric Acid 5.6 mg/dL, HDL-C 40 
mg/dL, LDL-C 105 mg/dL, Triglyceride 298 mg/dL, 
RBC 4.37 x 106/μL, Hb 13.3 g/dL, WBC 5400 /μL, Plt 
23.9 x 104/μL. Data concerning diabetes showed HbA1c 
9.0%, post-prandial glucose 283 mg/dL. 
 
    Other examinations were as follows: i) ECG: pulse 
76/min, ordinary sinus rhythm, no ST-T changes, ii) 
chest X-ray: WNL, iii) Ankle brachial index (ABI) / 
Pulse wave velocity (PWV): ABI showed 1.22/1.26 (r/l), 
and PWV 1715/1864 (>+2SD), iv) Coefficient of 
variation of R -R interval (CV R-R): it was 3.0% 
(normal is =< 2.0), v) renal examination: Ccr 80.2 
ml/min, Urinary-Albumin 10.8 mg/day, serum CPR 
1.71 ng/ml, vi) urinary C-peptide 92 μg/day (35-140). 
 
Clinical Progress 
    This case has T2DM and other problems. She was 
pointed out (P/O) the presence of left adrenal 
incidentaloma, and after that, the possibility of 
Cushing syndrome was ruled out (R/O) (Fig-1). She 
has been provided Ipragliflozin L-proline (Sugra®, 
50mg) 1 Tablet and Voglibose (Basen
®
, 0.3mg) 2 
Tablets in the morning and evening as oral 
hypoglycemic agents (OHAs) for long period. For
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injectable agents, she has given i) insulin glargine 10 
units and Apidra 17-25-18 units, which was MDI 
insulin therapy, ii) Deglutide 0.75mg/week, iii) 
Xultophy 10-18 doses/day as shown in Fig-1. HbA1c 
value was 9.0% to 7.8% in MDI, 7.8% to 10.6% in 
Deglutide, and 10.6% to 8.2% in Xultophy.  
 
 
Fig-1: Clinical progress with the changes of HbA1c and 
treatment 
 
    When changing the treatment from Deglutide to 
Xultophy, the daily profile of blood glucose was studied 
for 2 weeks. The results are shown in Table-1. 
Dulaglutide   has   its  clinical   effect   for  7   days,  and  
 
glucose levels ranged from 159 mg/dL to 208 mg/dL 
during days 6-8 after the injection of Dulaglutide. 
Xultophy was started at 10 doses and gradually 
increased its dose. Glucose variability was improved 
for 108 mg/dL to 144 mg/dL for 11-12 days of 
administration.  
 
Problems Lists:  
    Her current medical problems and treatment are 
summarized in the following. 
1. T2DM: She has been provided OHAs and three 
injectable agents during the course (Fig-1).  
2. Hypertension: Her blood pressure has been 
controlled by the administration of two anti-
hypertensive agents (AHA), including Irbesartan 
100mg and trichlormethiazide 1mg.  
3. Hyperlipidemia: She was given Rosuvastatin 
(Crestor®, 2.5mg) with rather stable control of 
LDL-C, TG and HDL-C [19]. 
4. Osteoarthritis (OA) of the knees: She has felt pain 
in the knees. Current treatment includes 
Celecoxib (Celecox®, 100mg) 2 Tablets per day 
and pregabalin (Lyrica® 75mg) 2 Tablets per day 
[20].
 
Table-1: Changes in blood glucose for Xultophy treatment 
Day 
Blood Glucose (mg/dL) Xultophy Dulaglutide  
Morning Noon Evening dose  0.75mg/w 
1     159   day 6 
2 194 196 166   day 7 
3 208 188 172   day 8 
4 189 164 175 10   
5 190 181 193 12   
6 149 149 252 14   
7 174 140 149 14   
8 149 115 174 16   
9 126 107 118 16   
10 131 122 162 16   
11 135 91 102 17   
12 119 111 101 17   
13 140 147 165 17   
14 124 111 144 17   
15 108 110   18   
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Discussion 
    This report is concerning to clinical efficacy of 
Xultophy, which contains basal-bolus insulin and GLP-
1RA. Several papers were found about the comparative 
study of basal insulin and Xultophy. Previous outcomes 
of Xultophy were broadly aligned with the results of 
DUAL studies. They showed a significant decrease in 
HbA1c, reducing the tendency of body weight, lower 
risk of hypoglycemia episodes for half years in 
comparison with baseline regimens [21]. Despite being 
an efficacious glucose-lowering therapy, basal-bolus 
treatment is associated with a higher rate of 
hypoglycemia versus other anti-diabetes therapies 
[22].  
 
    In the European region, there has been the 
European Xultophy Treatment Retrospective Audit 
(EXTRA) study. Some real-world evidence (RWE) 
studies (EXTRA) showed that a significant HbA1c 
reduction (-0.7%) and weight reduction (-2.4kg) were 
found for half a year, in patients with changing 
treatment from MDI to Xultophy [23]. There is a 
recent study by Persano et al. (2021) [24]. T2DM 
patients had changed from basal-bolus insulin 
treatment to Xultophy starting with 16 doses. Subjects 
were trained to titrate the dose twice weekly to 
maintain 90-130 mg/dL fasting target glucose level. 
Their adjustments were made 2 doses at a time. The 
results showed that HbA1c values were 8.4 vs 7.4% in 
the control and Xultophy group in 6 months [24]. 
 
    Regarding the background of the case, it is 
important to evaluate the situation of diabetic 
complications for microangiopathy and 
macroangiopathy. She has proliferative retinopathy 
with the treatment of photocoagulation and the 
operation of cataract but did not have clear evidence of 
neuropathy, nephropathy, or macroangiopathy of the 
brain, heart, and peripheral artery. When she received 
a health check-up in the spring of 2020, left adrenal 
incidentaloma was found. Several endocrinological 
tests showed negative results in plasma aldosterone 
concentration (PAC), plasma renin activity (PRA), 
PAC/PRA ratio [25], ACTH and cortisol values, 
overnight dexamethasone suppression test (1mg), and 
serum and urine catecholamine concentration. It was 
unlikely to  exist  the presence of  Cushing's syndrome, 
pheochromocytoma, or primary aldosteronism (PA) 
[26]. Therefore, it was considered to be a non-
functioning adenoma. 
 
    She has been treated for hypertension for a long. 
Her usual situation of blood pressure was stable with 
medication, not a fluctuating type, not clinical 
symptoms like pheochromocytoma, and catecholamine 
levels were within the normal range [27]. Since 
Cushing's disease is also negative, it is considered to be 
essential hypertension rather than secondary 
hypertension. Regarding dyslipidemia, triglyceride has 
been high for some time. In other words, it is thought 
to be associated with obesity and metabolic syndrome, 
and LDL-C is currently in the normal range by taking 
Crestor. A recent study showed the significant 
predominance of Rosuvastatin over atorvastatin in 
reducing LDL in T2DM as a mean reduction of 30.5 vs 
29.6 mg/dL for 6 weeks (p <0.01) [28].  
 
    Her current clinical course showed the exacerbation 
of HbA1c after changed to the treatment of Dulaglutide, 
and then the treatment of Xultophy was started. As the 
initial amount of Xultophy, 10 or 16 doses has been the 
standard value in a patient with insulin naïve or 
experienced case, respectively [29]. Furthermore, 
there may be another perspective that the standard 
starting dose would be 16 doses in Europe or 10 doses 
in Japan. This case is a Japanese woman with rather a 
small physique, then the starting dose was set to 10 
doses. Furthermore, authors have various experiences 
to provide Xultophy T2DM patients with various 
situations and complications [16,17]. The method to 
titrate would be to control the doses every 3-4 days 
based on FPG. In the study of DUAL V, attended cases 
had adjusted the doses on Monday and Thursday of 
each week [10]. The maximum doses of Xultophy 
would be 50 doses, which means 50 units of Degludec 
and 1.8 mg of liraglutide [13,29]. As to the 
continuation of Xultophy, 2432 T2DM cases were 
investigated for 18 months. The results showed that 
84% of cases continued Xultophy, associated with a 
mean reduction of HbA1c 1%, and weight reduction 1.1 
kg, by 33 mean doses [30]. 
 
    In summary, this article showed the impressive 
clinical progress of  the changes in  HbA1c  and diabetic 
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agents from MDI, Dulaglutide to Xultophy. Xultophy 
may have dual synergistic effects of degludec and 
liraglutide (IDegLira). Consequently, combined 
treatment of insulin and GLP-1RA seemed to be 
effective for improving the glucose variability. This 
report will be hopefully one of the reference data for a 
future diabetic research study. 
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